Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia

Karolinska University Hospital

Status and phase: Completed; Phase 2

Conditions: B-CLL

Treatments: Drug: alemtuzumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00162851

CAM219

Details and patient eligibility

About

This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced B-cell chronic lymphocytic leukemia (B-CLL).

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• B-CLL that has failed fludarabine

Exclusion criteria

• Performance status grade 3

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)